+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neoadjuvant chemotherapy as a model to accelerate progress in drug development for breast cancer



Neoadjuvant chemotherapy as a model to accelerate progress in drug development for breast cancer



Cancer Investigation 18(Suppl. 1): 58-60




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035373675

Download citation: RISBibTeXText


Related references

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clinical Cancer Research 21(13): 2911-2915, 2015

Neoadjuvant chemotherapy for breast cancer: any progress?. Lancet. Oncology 15(2): 131-132, 2014

Clinical and Molecular Methods in Drug Development: Neoadjuvant Systemic Therapy in Breast Cancer as a Model. Methods in Molecular Biology 1395: 251-280, 2016

Progress in evaluation of pathologic response to neoadjuvant chemotherapy of breast cancer. Anti-Cancer Agents in Medicinal Chemistry 13(2): 222-226, 2013

Impact of interstitial fluid pressure,tumor oxygenation, and chemotherapy drug sequencing on response to neoadjuvant chemotherapy breast cancer. 2007

Docetaxel was effective as neoadjuvant chemotherapy for patients after failure of trans-arterial neoadjuvant chemotherapy with CEF in 2 cases of advanced breast cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(11): 1743-1745, 2001

Development of malignant breast microcalcifications after neoadjuvant chemotherapy in advanced breast cancer. Breast Journal 10(2): 141-145, 2004

Developing CT image-processing tools to accelerate progress in lung cancer drug development. Oncology 20(12): 1606 1608, 2006

The development of neoadjuvant chemotherapy in breast cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(6): 876-881, 2012

Efficacy of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer: a meta-analysis of randomized controlled clinical trials. Zhejiang Da Xue Xue Bao. Yi Xue Ban 45(4): 379-386, 2016

A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy. Breast Cancer Research and Treatment 163(1): 11-19, 2017

Ultrasonographic tissue characterization in monitoring tumor response to neoadjuvant chemotherapy in locally advanced breast cancer (work in progress). Journal of Ultrasound in Medicine 19(10): 677-686, 2000

Effects of Neoadjuvant Chemotherapy on Benign Breast Lesions Compared to Cancers: Should an Additional Lesion on Magnetic Resonance Imaging Responding Similar to Cancer after Neoadjuvant Chemotherapy be Viewed with Suspicion?. Journal of Clinical Imaging Science 6: 39, 2016

MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Annals of Surgery 251(4): 701-707, 2010

Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. Journal of Clinical Oncology 22(13): 2576-2586, 2004